Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’

We recently published 10 Trending Stocks This Week. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks this week.

Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he recently bought Merck & Co Inc (NYSE:MRK).

“I think at some point the market turns towards quality. When you look at factors, this year has been about momentum. I think it’s going to turn to quality. I think that’s going to take the market directly towards healthcare, so I am looking to build exposure. I did that by buying Merck & Co Inc (NYSE:MRK).”

Impax US Sustainable Economy Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its second quarter 2025 investor letter:

“Merck & Co., Inc. (NYSE:MRK) (Health Care, Pharmaceuticals) has a high Corporate Resilience score, and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery. The stock’s weakness in Q2 was driven by a combination of concerns about its drug pipeline, particularly the competition from generic versions of Keytruda, and weaker market sentiment around Health Care stocks.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.